Table 1.

Baseline demographics between tetrabenazine and risperidone groups

	Tetrabenazine	Risperidone	P‐value
N	72	72
% Female	63.6	50.0	53.1
CAG, mean ± S.D.	44.26 ± 3.24	43.79 ± 3.18	0.379
Age0 (yrs), mean ± S.D.	53.77 ± 11.55	54.01 ± 11.85	0.904
AMO (yrs), mean ± S.D.	44.42 ± 10.63	46.72 ± 10.55	0.199
CAP0, mean ± S.D.	117.60 ± 14.82	114.47 ± 17.40	0.247
TMS0, mean ± S.D.	40.81 ± 17.70	39.56 ± 17.89	0.674
TFC0, mean ± S.D.	7.10 ± 3.20	7.24 ± 3.14	0.793
Weight0 (kg), mean ± S.D.	73.03 ± 15.80	77.50 ± 17.33	0.108
BMI0 (kg/m2), mean ± S.D.	25.57 ± 4.86	26.45 ± 4.79	0.272
Baseline depression score, mean ± S.D.	1.39 ± 2.53	3.09 ± 3.94	0.003
Baseline suicidality score, mean ± S.D.	0.07 ± 0.35	0.24 ± 0.75	0.082
Baseline aggression score, mean ± S.D.	0.83 ± 1.99	1.01 ± 2.16	0.603
Baseline irritability score, mean ± S.D.	1.99 ± 2.85	2.73 ± 3.70	0.178
Time between first and second visit (yrs), mean ± S.D.	1.09 ± 0.22	1.07 ± 0.25	0.641
Daily dose (mg), mean ± S.D.1	56.53 ± 41.17	1.76 ± 1.60	N/A
Prior time on therapy (yrs), mean ± S.D.	1.80 ± 2.05	2.39 ± 2.49	0.125
Medication indicated for chorea, %1	100	55.6	N/A

Abbreviations: AMO, Age of motor onset; BMI₀, Baseline body mass index; CAG, Cytosine‐Adenine‐Guanine; CAP₀, Baseline disease burden score calculated (age₀ x [CAG‐30]/6.27); TFC₀, Baseline Total Functional Capacity score; TMS₀, Baseline total motor score.

¹Statistical significance not calculated